PVLA — Palvella Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Palvella Therapeutics Announces Positive Topline Results From Phase 2 TOIVA Clinical Trial Of Qtorin™
Brief: Palvella Therapeutics Reports Third Quarter 2025 Financial Results And Provides Corporate Update
Brief: U.S. FDA awards Year Two funds to Palvella's Phase 3 Selva trial
Truist Securities raises PT on Palvella Therapeutics on lead drug potential
Brief: Palvella Therapeutics Announces Expansion of QTORIN Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
Brief: Palvella Completes Phase 2 TOIVA Trial Enrollment for QTORIN Rapamycin in Treating Cutaneous Venous Malformations
Brief: Palvella Therapeutics Strengthens Leadership With Appointment Of Accomplished Scientist And Biopharmaceutical Executive David W. Osborne, Ph.D. As Chief Innovation Officer
U.S. RESEARCH ROUNDUP-Applied Materials, Precigen, Transdigm Group
Palvella Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: Palvella Therapeutics Completes Enrollment In Phase 3 Selva Trial Of Qtorin™ Rapamycin For Microcystic Lymphatic Malformations, Exceeding Enrollment Target By Over 25%
Brief: Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026
Brief: Palvella Therapeutics Appoints Rare Disease Commercial Veteran Ashley Kline As Chief Commercial Officer
Palvella Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Palvella Therapeutics Inc expected to post a loss of $1.21 a share - Earnings Preview
Palvella Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Palvella Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax
U.S. STOCKS ON THE MOVE-OrganiGram, Phillips 66, SurgePays
Stifel initiates Palvella with 'buy' rating on skin treatment prospects